Clinical Trials in New York

Showing 2561-2580 of 22,668 trials

Outcomes of Low-Risk Endometrial Cancer With Isolated Tumor Cells in the Sentinel Lymph Nodes: A Prospective, Multicenter, Single-Arm Observational Study

NCT06689956

This study evaluates whether isolated tumor cells in the first lymph nodes near the tumor can tell researchers something important about the future of patients with a certain type of endometrial (uterine) cancer.

FIGO Grade 1 Endometrial Endometrioid AdenocarcinomaFIGO Grade 2 Endometrial Endometrioid AdenocarcinomaStage IA1 Endometrial Cancer FIGO 2023+1 more

Mayo Clinic212 participantsStarted Dec 2024

Rochester, Minnesota, United States • New York, New York, United States • Houston, Texas, United States +17 more locations

Active Not RecruitingPhase 1/2< 1 mile

Study of AZD5305 as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Malignancies

NCT04644068

This research is designed to determine if experimental treatment with PARP inhibitor, AZD5305, alone, or in combination with anti-cancer agents is safe, tolerable, and has anti-cancer activity in patients with advanced solid tumors.

Ovarian CancerBreast CancerPancreatic Cancer+10 more

AstraZeneca702 participantsStarted Nov 2020

Boston, Massachusetts, United States • Boston, Massachusetts, United States • New York, New York, United States +65 more locations

Outcomes of Low-Risk Endometrial Cancer With Isolated Tumor Cells in the Sentinel Lymph Nodes: A Prospective, Multicenter, Single-Arm Observational Study

Study of AZD5305 as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Malignancies

Find Trials by Condition in New York

Phase III Xevinapant (Debio 1143) and Radiotherapy in Resected LA SCCHN, High Risk, Cisplatin-ineligible Participants (XRAY VISION)

Mitigation of Postoperative Delirium in High-Risk Patients

Epco, Zanu, Ritux for R/R FL or MZL

RESTORE - Phase II

Longitudinal Endotyping Of Atopic Dermatitis Through Transcriptomic Skin Analysis

Combination Immunotherapy for the Treatment of Chemotherapy-refractory Metastatic MSS CRC

Data-driven SDM to Reduce Symptom Burden in AF

A Study of Pembrolizumab/Vibostolimab (MK-7684A) in Relapsed/Refractory Hematological Malignancies (MK-7684A-004, KEYVIBE-004)

A Study With Combinations of Anti-LAG-3 and Anti-PD-1 Antibodies in Adult Participants With Advanced or Metastatic Melanoma (Harmony Head-to-Head)

Support for Cancer Patients Awaiting News

Alcohol-ROC-Training

Veterans Affairs Lung Cancer Surgery Or Stereotactic Radiotherapy

DAY101 In Gliomas and Other Tumors

An Open-label Extension Trial to Evaluate the Long-term Safety of KVD900 (Sebetralstat) for On-Demand Treatment of Angioedema Attacks in Adolescent and Adult Patients With Hereditary Angioedema (HAE)

Efficacy and Safety Study of Pembrolizumab (MK-3475) With or Without Lenvatinib (MK-7902/E7080) in Adults With Programmed Cell Death-Ligand 1 (PD-L1)-Positive Treatment-naïve Nonsmall Cell Lung Cancer (NSCLC) (MK-7902-007/E7080-G000-314/LEAP-007)

Pediatric Adhesion and New Dermal Approach Study

An Early Access Study of Ivosidenib in Patients With a Pretreated Locally Advanced or Metastatic Cholangiocarcinoma

PF-07265028 As Single Agent And In Combination With Sasanlimab in Advanced or Metastatic Solid Tumors